← Human Trials & Peer-Reviewed Studies
Role of prehospital point-of-care N-terminal pro-brain natriuretic peptide in acute life-threatening cardiovascular disease
Plain-language guide to PMID 35716940 (2022): multicenter observational study of BNP (Nesiritide).
Key Facts
- PMID
- 35716940
- Journal
- International journal of cardiology
- Year
- 2022
- Study type
- Observational Study
- Authors
- Castro-Portillo E et al. (9 authors)
- DOI
- 10.1016/j.ijcard.2022.06.025
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as an observational study.
The main objective of this study is to assess the ability of point-of-care testing (POCT) N-terminal portion of B-type natriuretic peptide (NT-proBNP) to predict 2-day in-hospital mortality of acute cardiovascular diseases (ACVD).
Why It Was Studied
The evidence about the use of natriuretic peptides (NP) to predict mortality in the pre-hospital setting is limited.
Who Took Part
PubMed indexes the participants as adults and older adults, both men and women.
The researchers conducted a multicentric, prospective, observational study in adults with ACVD transferred by ambulance to emergency departments (ED).
How the Study Was Run
The researchers set it up as a multicenter study.
Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.
The primary outcome was 2-day in-hospital mortality.
The discrimination capacity of the NT-proBNP was performed through a prediction model trained using a derivation cohort and evaluated by the area under the curve (AUC) of the receiver operating characteristic on a validation cohort.
What Was Measured
PubMed files the paper under topics including Acute Disease, Biomarkers, Cardiovascular Diseases, Emergency Service, Hospital, Heart Failure, Natriuretic Peptide, Brain and Peptide Fragments.
Author keywords: Advanced cardiac life support, Brain natriuretic peptide, Emergency medical services, Heart diseases and Point-of-care testing.
What This Means in Plain Language
The paper is a multicenter study of BNP (Nesiritide).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (International journal of cardiology), a journal based in Netherlands.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.